Rheumatoid arthritis therapy - Apollo Life Sciences

Drug Profile

Rheumatoid arthritis therapy - Apollo Life Sciences

Alternative Names: ALS-00T2 oral - Apollo Life Sciences; Oral TNF blocker for rheumatoid arthritis - Apollo Life Sciences

Latest Information Update: 09 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apollo Life Sciences
  • Class
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 14 Feb 2007 Preclinical data added to the Rheumatic Disease pharmacodynamics section
  • 14 Oct 2006 Preclinical trials in Rheumatoid arthritis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top